What's new? Log in Free sign up

Castle Biosciences (CSTL)

Company Profile

Company profile

Ticker

CSTL

Exchange

Website

castlebiosciences.com

CEO

Mr. Derek J. Maetzold

Incorporated

Location

Fiscal year end

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Laboratory Corporation of America • Fortrea • GRAIL • RadNet • Akumin • Oxford Square Capital • Burning Rock Biotech Limited • Guardant Health • Exact Sciences ...

Former names

POTLATCH CORP, Potlatch Holdings, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AltheaDx, Inc. • Cernostics, Inc. • Myriad myPath, LLC • Castle Narnia Way Real Estate Holding 1, LLC ...

IRS number

770701744

CSTL stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

Quarterly report

4 Nov 24

Castle Biosciences Reports Third Quarter 2024 Results

Quarterly report

5 Aug 24

Castle Biosciences Reports Second Quarter 2024 Results

Submission of Matters to a Vote of Security Holders

Additional proxy soliciting materials

Quarterly report

2 May 24

Castle Biosciences Reports First Quarter 2024 Results

Notice of effectiveness

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

DEREK J MAETZOLD

DANIEL BRADBURY

DEREK J MAETZOLD

Tobin W Juvenal

Notice of proposed sale of securities

DEREK J MAETZOLD

DEREK J MAETZOLD

Notice of proposed sale of securities

Tobin W Juvenal

Financial summary

Financial statements Chart CSTL financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	94.96 mm	94.96 mm	94.96 mm	94.96 mm	94.96 mm	94.96 mm
Cash burn (monthly)	(no burn)	(no burn)	(no burn)	86.50 k	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	n/a	368.36 k	n/a	n/a
Cash remaining	n/a	n/a	n/a	94.59 mm	n/a	n/a
Runway (months of cash)	n/a	n/a	n/a	1093.5	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

CSTL institutional ownership history Ownership history

99.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	188	159	+18.2%
Opened positions	44	35	+25.7%
Closed positions	15	25	-40.0%
Increased positions	71	51	+39.2%
Reduced positions	47	47	–

13F shares	Current	Prev Q	Change
Total value	694.88 bn	522.98 bn	+32.9%
Total shares	27.90 mm	27.35 mm	+2.0%
Total puts	15.30 k	130.10 k	-88.2%
Total calls	302.60 k	510.80 k	-40.8%
Total put/call ratio	0.1	0.3	-80.1%

Largest owners	Shares	Value	Change
BlackRock	3.12 mm	$88.99 bn	NEW
Wasatch Advisors	1.83 mm	$52.08 bn	-21.6%
Vanguard	1.75 mm	$49.87 bn	+10.9%
PFG Principal Financial	1.54 mm	$43.88 bn	+2.7%
BLVGF Bellevue	1.26 mm	$35.99 bn	+3.7%
Portolan Capital Management	1.26 mm	$35.81 bn	+3.7%
Sofinnova HealthQuest Partners	983.58 k	$52.32 mm	0.0%
Dimensional Fund Advisors	864.82 k	$24.66 bn	+6.8%
Bradbury Daniel	743.42 k	$49.92 mm	0.0%
STT State Street	680.00 k	$19.39 bn	+9.8%

Largest transactions	Shares	Bought/sold	Change
BlackRock	3.12 mm	+3.12 mm	NEW
BLK BlackRock	0.00	-3.04 mm	EXIT
Deerfield Management	16.94 k	-857.67 k	-98.1%
Granahan Investment Management	425.22 k	-633.72 k	-59.8%
Wasatch Advisors	1.83 mm	-501.84 k	-21.6%
Point72 Asset Management	499.19 k	+445.42 k	+828.3%
Nuveen Asset Management	542.59 k	+256.08 k	+89.4%
Deutsche Bank AG - Registered Shares	60.17 k	-249.34 k	-80.6%
Silvercrest Asset Management	201.92 k	+201.92 k	NEW
Soleus Capital Management	662.33 k	-191.30 k	-22.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CSTL insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	29.48	4	117.92	5,104
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	29.48	5	147.40	5,104
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	29.48	4	117.92	5,104
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	29.48	5	147.40	5,110
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	29.48	15	442.20	60,573
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	29.48	16	471.68	71,081
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	No	Yes	29.48	31	913.88	80,818
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	28.65	61	1.75 k	5,108
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	28.65	60	1.72 k	5,109
13 Jan 25	Maetzold Derek J	Common Stock	Sell	Dispose S	Yes	Yes	28.65	61	1.75 k	5,108

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments

2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023Year-end 2024 cash,

Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

TissueCypher is the first AI-driven precision medicine test designed to predict a patient's individual risk of progression from Barrett's esophagus (BE) to esophageal cancer.With this approval, all of the tests in

Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock

Stephens & Co. Reiterates Overweight on Castle Biosciences, Maintains $41 Price Target

Castle Biosciences Advances Test to Predict Super Response in Atopic Dermatitis

Press releases

From Benzinga Pro

Castle's Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

Highlights from Castle's DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time Castle Biosciences, Inc.

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test

With this approval, all of the tests in Castle's dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New

Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.